From: Impact of intraoperative lung-protective interventions in patients undergoing lung cancer surgery
Characteristic | Unadjusted analysis | Adjusted analysis | ||
---|---|---|---|---|
 | Odds ratio (95% confidence interval) | P value | Odds ratio (95% confidence interval) | P value |
Age, per 10-year increase | 1.09 (0.80 to 1.89) | 0.382 | - | - |
Chronic alcohol consumption | 1.76 (1.11 to 5.2) | 0.013 | 1.93 (1.14 to 5.71) | 0.001 |
FEV1 < 60% | 1.12 (0.78 to 2.05) | 0.254 | - | - |
ASA class 3/4 | 1.21 (0.72 to 2.21) | 0.214 | - | - |
ACE inhibitor therapy | 0.85 (0.55 to 2.12) | 0.315 | - | - |
Statin therapy | 0.81 (0.45 to 2.97) | 0.198 | - | - |
Chemo-radiotherapy | 1.52 (1.09 to 3.83) | 0.021 | 1.40 (0.91 to 2.98) | 0.203 |
Advanced TNM stages (III to IV) | 1.63 (1.09 to 3.01) | 0.018 | 1.45 (0.87 to 2.84) | 0.234 |
Thoracic epidural anesthesia | 0.92 (0.78 to 1.92) | 0.563 | - | - |
Duration of surgery | 1.37 (0.78 to 2.67) | 0.312 | - | - |
Red blood cell transfusion | 1.09 (0.23 to 7.24) | 0.789 | - | - |
Pneumonectomy | 2.41 (1.29 to 8.12) | 0.005 | 2.52 (1.34 to 7.71) | < 0.001 |
Fluid infused, per 1 ml/kg/hour increase | 1.33 (1.02 to 5.08) | 0.032 | 1.42 (1.09 to 4.32) | 0.011 |